Heteroaryl compounds which inhibit leukocyte adhesion mediated by .alpha..sub.4 integrins
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 26, 2008
Grant Date -
Jun 16, 2005
app pub date -
May 27, 2003
filing date -
May 24, 2002
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Disclosed are compounds which bind .alpha..sub.4 integrins, where the .alpha..sub.4 integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by .alpha..sub.4 integrins, where the .alpha..sub.4 integrin is preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully